Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Revenue projections:

Revenue projections for CAPLIPOINT
Revenue projections for CAPLIPOINT

With Caplin Point Laboratories Limited's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 18.472708
debtToEquity 0.166000
earningsGrowth 0.183000
revenueGrowth 0.101000
grossMargins 0.592320
operatingMargins 0.313960
trailingEps 80.540000
forwardEps 91.600000

CAPLIPOINT's Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
CAPLIPOINT's positive earnings and revenue growth signal the company's business is on track for further expansion. These strong financial trends suggest that CAPLIPOINT will continue to grow its operations, driven by increasing profits and revenue.
Caplin Point Laboratories Limited's positive gross and operating margins indicate a profitable and efficient business model. These metrics highlight the company's ability to generate income while controlling operational costs, reflecting strong financial performance.
CAPLIPOINT's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for CAPLIPOINT
Price projections for CAPLIPOINT

The price of Caplin Point Laboratories Limited currently aligns with projections, offering no clear risks or opportunities. This situation suggests stability in the stock's performance, leading investors to await further developments before making strategic decisions.

Recommendation changes over time:

Recommendations trend for CAPLIPOINT
Recommendations trend for CAPLIPOINT


Analysts have shown a buy bias for CAPLIPOINT, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to CAPLIPOINT, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.